×
戻る Agenda
Session 5: Platform Technologies: An Approach to Development and Regulation
Session Chair(s)
Representative Invited
DIA, Switzerland
This discussion will explore genome editing as a platform technology in cell and gene therapy, learn about recent advancements in precision medicine, and assess its broader therapeutic applications and role in regenerative medicine. Attendees will gain insights into the challenges faced when scaling these therapies, regulatory and manufacturing considerations, and are encouraged to share their own experience and strategies for ensuring safety, efficacy, and accessibility.
Learning Objective : - Learn how genome editing functions as a platform technology in cell and gene therapy development
- Differentiate key regulatory and manufacturing considerations for scaling genome-edited therapies
- Discuss the potential challenges and opportunities in integrating genome editing into regenerative medicine
Speaker(s)
Speaker
Michael Lehmicke, MSc
Alliance for Regenerative Medicine, United States
Senior Vice President, Science and Industry Affairs